Korro Bio推出价值7000万美元的PIPE产品

• Korro Bio (NASDAQ:KRRO) said Thursday it would raise $70 million through a private placement offering.
• The company has entered into a subscription agreement with certain new and existing accredited investors to issue and sell an aggregate of 1,249,283 shares.
• The PIPE was led by funds affiliated with Deep Track Capital, with participation from Atlas Venture, Blue Owl Healthcare Opportunities, NEA, Rock Springs Capital, Tri Locum Partners, and other leading healthcare investors.
• The company expects that the net proceeds from the PIPE along with its existing cash and equivalents of $166.4 million as of December 31, 2023, will provide runway to fund the completion of a Phase 1/2 trial of KRRO-110 in ZZ AATD patients, anticipated in 2026, among other things.
• Piper Sandler is acting as lead placement agent and RBC Capital Markets and BMO Capital Markets are acting as co-placement agents for the PIPE.
• Press Release.

More on Korro Bio

• Korro Bio: An Interesting Platform With A Very Long Horizon
• BMO starts Korro at outperform, cites upcoming data for AATD drug
• Historical earnings data for Korro Bio, 
• Financial information for Korro Bio,